ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that develops anticancer therapeutics using its Targeted Antibody Payload (TAP) technology and antibody expertise, today announced the appointment of Charles Morris, MB, ChB, MRCP as Executive Vice President and Chief Development Officer, effective today. Dr. Morris will be responsible for leading all aspects of product development, including regulatory, at ImmunoGen. He reports to Daniel Junius, President and Chief Executive Officer. “Charlie has extensive experience leading the strategic development and registration of novel oncology compounds – expertise essential to ImmunoGen with our advancing and expanding product pipeline,” commented Mr. Junius. “We now have three wholly owned clinical-stage compounds, expect to advance our fourth product candidate into the clinic in 2013, and have additional highly promising compounds behind these in our pipeline. We are excited to have Charlie joining ImmunoGen at this important time in our transition to being a product development company.” Dr. Morris brings to ImmunoGen nearly twenty years of experience in the development of anticancer compounds, including experience with registration clinical trials, regulatory approvals, pharmacovigilance, and medical affairs support for marketed products. Prior to joining ImmunoGen, he was the executive vice president and chief medical officer at Allos Therapeutics, Inc., where he led the company’s clinical development functions including clinical operations, regulatory, and pharmacovigilance. Prior to joining Allos in 2010, Dr. Morris was vice president worldwide clinical research at Cephalon, Inc., where he contributed significantly to the company achieving its first approved oncology drug, Treanda® (bendamustine). Prior to joining Cephalon in 2007, Dr. Morris was with AstraZeneca Pharmaceuticals (formerly Zeneca Pharmaceuticals), serving most recently as vice president, clinical development projects, oncology. Dr. Morris held a number of leadership roles during his more than ten years with AstraZeneca, including managing the clinical development of all late-stage pipeline and marketed oncology products. Dr. Morris holds Degrees of Bachelor of Medicine, Bachelor of Surgery, and Bachelor of Medical Science in Clinical Pharmacology and Therapeutics from the Sheffield University Medical School, UK, and is a member of the Royal College of Physicians of London.